It sounds like Lilly did just that. The U.S. pharma announced on Wednesday that it was paying $14 per share of Ventyx—more ...
GlobalData on MSN
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.
Investor's Business Daily on MSN
How Eli Lilly's plan to buy Ventyx for $1.2 billion could benefit Neumora, Neurocrine
Eli Lilly'sLLY $1.2 billion plan to buy Ventyx BiosciencesVTYX could benefit NeumoraNMRA and Neurocrine BiosciencesNBIX, an ...
Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...
Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...
The about-$1 billion deal could come imminently.
Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma company for over $1 billion.
Eli Lilly has announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, a biopharmaceutical ...
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space ...
The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...
Eli Lilly and Company has entered a definitive agreement to acquire Ventyx Biosciences Inc., a San Diego-based clinical-stage ...
Eli Lilly & Co. is in advanced talks to acquire Ventyx Biosciences Inc. for more than $1 billion to expand its work in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback